Entecavir was more effective than lamivudine in HbeAg-positive chronic hepatitis B

July 2006
ACP Journal Club;Jul/Aug2006, Vol. 145 Issue 1, p18
Academic Journal
This article presents information on a medical study where relative efficacy and safety of entecavir was determined in comparison to lamivudine. Patients with HBeAg-positive chronic hepatitis B without prior nucleoside analogue treatment were subjects of the study. Greater histologic improvement was noticed among the patients who received entecavir in comparison to the patients who received lamivudine. Also, a few of patients were unable to discontinue the study because of the adverse side effects of entecavir. It implies that subjects were well able to tolerate entecavir.


Related Articles

  • Telbivudine for Chronic Hepatitis B. A Review. Palumbo, Emilio // Anti-Infective Agents in Medicinal Chemistry;2008, Vol. 7 Issue 4, p245 

    Three hundred and fifty million people worldwide are estimated to be chronically infected with hepatitis B virus. 15%-40% of these subjects will develop cirrhosis, liver failure or hepatocellular carcinoma during their life. Approved drugs for chronic hepatitis B treatment include: standard...

  • Agreement of expert judgment in causality assessment of adverse drug reactions. Arimone, Yannick; Bégaud, Bernard; Miremont-Salamé, Ghada; Fourrier-Réglat, Annie; Moore, Nicholas; Molimard, Mathieu; Haramburu, Françoise // European Journal of Clinical Pharmacology;May2005, Vol. 61 Issue 3, p169 

    Background: Global introspection is, with operational algorithms and Bayes' theorem, one of the three main approaches used to assess the causal relationship between a drug treatment and the occurrence of an adverse event. Objective: To analyze and compare the judgments of five senior experts...

  • Real-World Experiences with Tenofovir Disoproxil Fumarate: Is this the "B-Ticket"? Terrault, Norah; Terrault, Norah A // Digestive Diseases & Sciences;Oct2016, Vol. 61 Issue 10, p2770 

    No abstract available.

  • Peginterferon-α-2b.  // Reactions Weekly;4/30/2005, Issue 1049, p13 

    Discusses research being done on a man who developed psoriasis during treatment with peginterferon-α-2b for chronic hepatitis B. Reference to a study by I. Ketikoglou, S. Karatapanis, I. Elefsiniotis, G. Kafiri and A. Moulakakis, published in the March-April 2005 issue of the "European...

  • lamivudine. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p456 

    An encyclopedia entry for "lamivudine" is presented. It refers to a reverse transcriptase inhibitor drug that slows the progression of HIV infection. Aside from HIV infection, the drug is also used in the treatment of longstanding hepatitis B infections. Some of the common side effects of the...

  • Calcium hydroxylapatite.  // Reactions Weekly;1/5/2008, Issue 1183, p9 

    This article presents information on the medical case of a 74-year-old woman who experienced early urethral prolapse after transurethral injection of calcium hydroxylapatite and distal urethrectomy. The patient developed stress urinary incontinence after undergoing distal urethrectomy for...

  • Adefovir/lamivudine.  // Reactions Weekly;Aug2015, Vol. 1564 Issue 1, p17 

    The article presents case studies of two patients who developed resistance to the treatment of adefovir and/or lamivudine for HBeAg-positive chronic hepatitis B.

  • Antineoplastics.  // Reactions Weekly;Nov2015, Vol. 1577 Issue 1, p31 

    The article presents a case study of a 28-year old woman with acute myeloid leukaemia who was successfully treated with lamivudine for acute hepatitis B that developed while receiving treatment of idarubicin.

  • Individual Variations in Drug Responses. Ward-Smith, Peggy // Urologic Nursing;Jan/Feb2010, Vol. 30 Issue 1, p22 

    The article offers an overview of the modifiable and non-modifiable variables that affect drug responses, such as health care conditions, race and ethnicity. Influences on drug responses that can and cannot be modified are described. It discusses ways on how nurses can influence compliance and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics